Mark Zervas

Mark Zervas earned his Ph.D in Neuroscience at the Albert Einstein College of Medicine, was a postdoctoral fellow at the NYU School of Medicine, and was the Manning Assistant Professor of Biology in the MCB department at Brown University. Mark served as Senior Scientist at Amgen, where he led a research team that used human genetics to discover novel therapeutic targets and hIPSC-derived dopamine neurons for understanding target biology and mechanisms underlying Parkinson’s Disease, including mitochondrial dysfunction. Most recently, Mark led a team at Alnylam Pharmaceuticals using RNAi to treat ocular diseases.